FEMASYS INC (FEMY): Price and Financial Metrics
GET POWR RATINGS... FREE!
FEMY Stock Summary
- With a market capitalization of $13,467,515, FEMASYS INC has a greater market value than merely 5.09% of US stocks.
- With a one year PEG ratio of 0.54, FEMASYS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.96% of US stocks.
- FEMY's went public 1.47 years ago, making it older than just 4.57% of listed US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to FEMASYS INC, a group of peers worth examining would be ADMP, VAXX, SNGX, OCFT, and PALT.
- To check out FEMASYS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001339005.
FEMY Valuation Summary
- In comparison to the median Healthcare stock, FEMY's price/sales ratio is 465% higher, now standing at 11.3.
- FEMY's EV/EBIT ratio has moved up 21.7 over the prior 18 months.
Below are key valuation metrics over time for FEMY.
FEMY Stock Price Chart Interactive Chart >
FEMY Price/Volume Stats
|Current price||$1.19||52-week high||$5.64|
|Prev. close||$1.14||52-week low||$0.99|
|Day high||$1.22||Avg. volume||174,440|
|50-day MA||$1.22||Dividend yield||N/A|
|200-day MA||$1.73||Market Cap||14.06M|
FEMASYS INC (FEMY) Company Bio
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Most Popular Stories View All
FEMY Latest News Stream
|Loading, please wait...|
FEMY Latest Social Stream
View Full FEMY Social Stream
Latest FEMY News From Around the Web
Below are the latest news stories about FEMASYS INC that investors may wish to consider to help them evaluate FEMY as an investment opportunity.
Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
--FemaSeed de novo trial enrollment has accelerated with trial recruitment focus on male factor infertility--ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has completed over 25% of its targeted enrollment (214 patient fertility cycles) in its FemaSeed® de novo tria
ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on AppLovin (APP – Research Report) and Femasys (FEMY – Research Report) with bullish sentiments. AppLovin (APP) Goldman Sachs analyst Eric Sheridan maintained a Buy rating on AppLovin on November 10 and set a price target of $33.00. The company's shares closed last Friday at $16.94, close to its 52-week low of $13.20. According to TipRanks.
Femasys ( NASDAQ:FEMY ) Third Quarter 2022 Results Key Financial Results Net loss: US$2.98m (loss widened by 32% from...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Femasys (FEMY - Research Report) yesterday and set a price target of $5.00. The company's shares opened today at $1.20.According to TipRanks, McCarthy is an analyst with an average return of -39.6% and a 14.32% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Immutep, and Actinium Pharmaceuticals.Femasys has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, which is a 316.67% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
FEMY Price Returns